Education
About Us
Working with TipRanks
Follow Us
FBT - ETF AI Analysis
Top Page
First Trust NYSE Arca Biotechnology Index Fund (FBT)
Rating:72Outperform
Price Target:―
Positive Factors
Strong Biotech Leaders in Top Holdings
Several of the largest positions, including Moderna and other key biotech names, have shown strong year-to-date gains, helping support the fund’s overall results.
Solid Recent Performance Momentum
The ETF has delivered strong performance over the last three months, indicating positive recent momentum in its holdings.
Meaningful Fund Size
With over a billion dollars in assets, the fund is large enough to offer good liquidity and stability for everyday investors.
Negative Factors
High Sector Concentration in Health Care
Almost all of the ETF’s assets are in the health care sector, so its performance is heavily tied to the fortunes of biotech and related companies.
Limited Geographic Diversification
The fund is almost entirely invested in U.S. companies, offering little protection if the U.S. market or regulatory environment for biotech weakens.
Above-Average Expense Ratio
The ETF’s fee is on the higher side for a passive index fund, which can slightly reduce long-term returns compared with lower-cost alternatives.
FBT vs. SPDR S&P 500 ETF (SPY)
AUM2.38B
RegionNorth America
Expense Ratio0.54%
Beta0.74
IssuerFirst Trust
Inception DateJun 19, 2006
Dividend YieldN/A
Asset ClassEquity
Index TrackedNYSE Arca Biotechnology Index
Share Statistics
EPS (TTM)N/A
Shares OutstandingN/A
10 Day Avg. Volume71,755
30 Day Avg. Volume169,405
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
257.93Price Target Upside― Downside
Rating ConsensusModerate Buy
Number of Analyst Covering30
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
FBT Summary
FBT is an ETF that follows the NYSE Arca Biotechnology Index, focusing on U.S. biotech companies developing new drugs, genetic treatments, and medical technologies. It holds well-known names like Moderna and Amgen, along with many smaller, innovative firms. Someone might invest in FBT if they want targeted exposure to the potential growth of cutting-edge health care and to diversify within the health sector. However, biotech stocks can be very volatile, and FBT’s value can swing sharply based on drug trial results, regulation changes, and overall market conditions.
How much will it cost me?The expense ratio for the First Trust NYSE Arca Biotechnology Index Fund (FBT) is 0.54%, which means you’ll pay $5.40 per year for every $1,000 invested. This is higher than average because the fund is actively managed, focusing on a niche sector like biotechnology that requires specialized research and expertise.
What would affect this ETF?The First Trust NYSE Arca Biotechnology Index Fund (FBT) could benefit from advancements in biotechnology and increased demand for innovative medical solutions, especially as the U.S. health care sector continues to grow. However, it may face challenges from regulatory changes, high research costs, or broader economic downturns that could impact funding and investor sentiment in the biotech industry.
FBT Top 10 Holdings
FBT is a pure-play U.S. biotech fund, and its story is all about drug developers on the front lines of innovation. Gilead, Amgen, and Vertex are the steady engines, rising on solid earnings and dependable franchises. Biogen and BioMarin add more fuel with improving momentum and promising pipelines. On the flip side, Moderna and BioNTech, once market darlings, are losing some steam as COVID-era tailwinds fade, creating a bit of drag. Overall, performance is driven by a concentrated mix of mid- to large-cap biotech innovators rather than broad market exposure.
Name | Company Name | Weight % | Market Value | Market Cap | Yearly Gain | Overall Rating |
|---|---|---|---|---|---|---|
| Moderna | 4.98% | $118.30M | $18.21B | 40.36% | 59 Neutral | |
| Gilead Sciences | 4.28% | $101.72M | $189.50B | 37.70% | 78 Outperform | |
| Amgen | 3.93% | $93.49M | $204.70B | 23.68% | 77 Outperform | |
| BioNTech SE | 3.78% | $89.75M | $25.96B | -8.22% | 53 Neutral | |
| BioMarin Pharmaceutical | 3.72% | $88.44M | $11.88B | -6.11% | 75 Outperform | |
| Alkermes | 3.68% | $87.53M | $5.29B | -9.65% | 80 Outperform | |
| BeOne Medicines | 3.67% | $87.20M | $42.27B | 41.81% | 61 Neutral | |
| Argenx Se | 3.67% | $87.17M | $51.98B | 31.02% | 79 Outperform | |
| Vertex Pharmaceuticals | 3.52% | $83.63M | $119.47B | -1.52% | 78 Outperform | |
| Biogen | 3.50% | $83.27M | $28.49B | 36.54% | 74 Outperform |
FBT Technical Analysis
Negative
―
Price Trends
212.29
Negative
203.92
Positive
185.20
Positive
Market Momentum
-1.31
Positive
44.16
Neutral
49.33
Neutral
Evaluating momentum and price trends is crucial in ETF analysis to make informed investment decisions. For FBT, the sentiment is Negative. The current price of undefined is equal to the 20-day moving average (MA) of 212.48, equal to the 50-day MA of 212.29, and equal to the 200-day MA of 185.20, indicating a neutral trend. The MACD of -1.31 indicates Positive momentum. The RSI at 44.16 is Neutral, neither overbought nor oversold. The STOCH value of 49.33 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for FBT.
FBT Peer Comparison
Comparison Results
Performance Comparison
FBT
First Trust NYSE Arca Biotechnology Index Fund
208.50
30.06
16.85%
IBB
iShares Biotechnology ETF
―
―
―
XBI
SPDR S&P BIOTECH ETF
―
―
―
IHI
iShares U.S. Medical Devices ETF
―
―
―
IYH
iShares U.S. Healthcare ETF
―
―
―
FHLC
Fidelity MSCI Health Care Index ETF
―
―
―
Glossary
BuyAn ETF rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF is likely to deliver higher returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldAn ETF rated as a "Hold" s expected to perform in line with the overall market or a specific benchmark. This rating indicates that the ETF is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellAn ETF rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF may deliver lower returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst ETF Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in ETFs carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: ―
Table of Contents